Personalized Stem Cells, Inc. (PSC) Company Profile

Background

Founded in 2018, Personalized Stem Cells, Inc. (PSC) is a privately held biopharmaceutical company based near San Diego, California. PSC specializes in advancing human regenerative medicine by developing FDA-compliant autologous stem cell therapies derived from a patient's own adipose (fat) tissue. The company's mission is to provide high-quality stem cell processing services and comprehensive support to physicians, clinical investigators, and patients, adhering strictly to FDA regulations to ensure safety and efficacy.

Key Strategic Focus

PSC's strategic focus centers on developing and commercializing autologous stem cell therapies for various medical conditions, particularly those with limited treatment options. The company emphasizes:

Orthopedic Applications: Initiating clinical trials targeting osteoarthritis and other musculoskeletal disorders.

Neurological Conditions: Exploring treatments for traumatic brain injuries and related ailments.

Inflammatory Diseases: Developing therapies for conditions such as COVID-19-induced acute respiratory distress syndrome (ARDS).

By leveraging its proprietary technologies and adhering to FDA guidelines, PSC aims to provide safe and effective regenerative treatments to patients.

Financials and Funding

In July 2020, PSC secured $2.5 million in a Series A financing round led by seed investors and key opinion leaders in the field. The funds were allocated to complete the ongoing FDA-approved osteoarthritis clinical trial and to initiate clinical trials for traumatic brain injury, back pain, and COVID-19 treatments.

Pipeline Development

PSC's pipeline includes several key candidates:

Knee Osteoarthritis: In July 2019, PSC received FDA approval for a New Drug (IND) application to conduct clinical trials using autologous adipose-derived stem cells to treat knee osteoarthritis. The Phase 1/2a clinical trial enrolled 38 patients, with enrollment completion announced in August 2020.

COVID-19 Treatment: In April 2020, PSC collaborated to rapidly bring a stem cell therapy into clinical trials for COVID-19 patients. The objective of this non-randomized, Phase 1b study was to evaluate the safety and preliminary efficacy of adipose-derived stem cell therapy for the treatment of ARDS resulting from infection with COVID-19.

Traumatic Brain Injury and Back Pain: PSC plans to initiate clinical trials targeting these conditions, utilizing its autologous stem cell therapies.

Technological Platform and Innovation

PSC's technological platform is distinguished by:

Proprietary Technologies: Utilizing advanced methods for extracting and processing adipose-derived stem cells, ensuring high-quality and consistent cell products.

Scientific Methodologies: Employing cutting-edge lab techniques and adhering to Current Good Manufacturing Practices (CGMP) to maintain safety and efficacy standards.

FDA Compliance: Operating within FDA regulations to provide stem cell therapies that are both safe and effective, distinguishing PSC from unregulated in-clinic stem cell processing.

Leadership Team

Dr. Bob Harman, DVM, MPVM: Chief Executive Officer of PSC and VetStem Biopharma. Dr. Harman brings extensive experience in regenerative medicine and biotechnology entrepreneurship.

Dr. Chris Rogers, MD: Medical Director. Dr. Rogers is a leader in regenerative medicine, contributing significantly to PSC's clinical development strategies.

Stephen Keane: Chief Business Development Officer. Mr. Keane focuses on expanding PSC's market presence and forging strategic partnerships.

Corbyn May, MBA: Director of Commercial Operations. Mr. May oversees the commercialization of PSC's therapies and operational management.

Leadership Changes

In April 2022, PSC announced the appointment of Dr. Anne S. Hale as Chief Development Officer, enhancing the company's leadership in clinical development and regulatory affairs.

Competitor Profile

Market Insights and Dynamics

The regenerative medicine market is experiencing significant growth, driven by advancements in stem cell research and increasing demand for innovative therapies. Key trends include the development of personalized treatments and the expansion of clinical applications for stem cell therapies.

Competitor Analysis

Cellular Dynamics International (CDI): Specializes in developing human cells for drug discovery, toxicity testing, and regenerative medicine applications. CDI's MyCell® Products enable customer-provided donor samples to be reprogrammed, gene-edited, and differentiated.

EpiBone: Focuses on creating bone tissue from a patient's mesenchymal stem cells for use in bone grafts, offering personalized skeletal reconstruction solutions.

Pluri Inc.: Develops placenta-based cell therapies for various indications, including critical limb ischemia and muscle injury, leveraging its proprietary 3D cell expansion technology.

Lineage Cell Therapeutics: Develops novel cell therapies for unmet medical needs, with programs targeting age-related macular degeneration, spinal cord injuries, and cancer immunotherapy.

Mesoblast: An Australian company focusing on regenerative medicine, developing treatments for inflammatory ailments, cardiovascular disease, and back pain using mesenchymal lineage cells.

Strategic Collaborations and Partnerships

PSC has engaged in significant collaborations to enhance its research and development capabilities:

VetStem Biopharma: PSC's sister company, VetStem, has provided foundational support, including licensing a portfolio of patents and applications in regenerative medicine.

Sorrento Therapeutics: PSC licensed its COVID-19 stem cell therapy technology to Sorrento Therapeutics, facilitating the rapid advancement of treatments for COVID-19 patients.

Operational Insights

PSC's strategic considerations include:

Regulatory Compliance: Strict adherence to FDA guidelines ensures the safety and efficacy of its therapies, distinguishing PSC from unregulated competitors.

Manufacturing Capabilities: The acquisition of new manufacturing facilities in March 2023 has enhanced PSC's capacity to produce GMP-compliant stem cell products, supporting its clinical trials and commercialization efforts.

Clinical Network: PSC has established a network of experienced physicians and clinical trial sites across the United States, facilitating the efficient execution of its clinical programs.